AI-Designed Universal Coronavirus Vaccine Completes First Human Safety Trial

The risk from coronaviruses does not come only from known COVID-19 variants. It also comes from related viruses that have not yet crossed into human populations, but may be accumulating mutations in animal hosts. The Phase I human trial announced by the Cambridge team and its spin-out company DIOSynVax is notable not because it has already proved it can stop the next outbreak, but because it has advanced an AI-designed broad-spectrum vaccine concept to its first test of safety and immune response in humans.

According to information released by the University of Cambridge, the Sarbeco coronavirus candidate vaccine, named pEVAC-PS, has completed a Phase I, needle-free delivery, dose-escalation clinical trial in 39 healthy volunteers. The university said the trial found no major safety concerns or significant side effects, and observed immune responses against SARS-CoV-2, SARS virus, and related bat coronaviruses. The related paper was published in the Journal of Infection, and Cambridge said a larger Phase II trial is being planned.

At the core of the technology is the use of computational methods to design a “superantigen” vaccine payload, seeking to identify immune targets that are more conserved across an entire family of viruses and less likely to disappear with mutation, rather than merely chasing a single circulating strain. The candidate vaccine is given as a DNA vaccine and delivered into the skin through a microfluidic needle-free jet device. This is connected to the direction of the team’s earlier DIOS-CoVax2 program, when Cambridge had described its use of libraries of genetic sequences from known coronaviruses, including bat coronaviruses, to generate antigenic structures that could be encoded by synthetic genes.

For biomedical AI, the key here is not the phrase “AI-designed” itself, but whether the antigen produced by the algorithm can be read by the immune system and generate measurable, reproducible responses in humans, ideally ones that also span viral branches. The Phase I data provide clues on safety and immunogenicity. They cannot yet answer whether the vaccine can prevent infection, reduce severe disease, or provide clinical protection against newly emerging viruses in the future. The sample size of only 39 people also means that rare adverse reactions and effects in populations with different ages and disease backgrounds still need to be addressed in larger studies.

This line of research and development did not appear suddenly. In 2022, CEPI announced that it would invest up to $42 million to support DIOSynVax in developing a broadly protective Betacoronavirus vaccine, with targets covering existing and future SARS-CoV-2 variants as well as a wider range of coronavirus threats, including viruses related to SARS and MERS. That funding context shows that this trial is not an extension of a single COVID-19 booster vaccine, but part of a post-pandemic shift in global vaccine development toward “prototype pathogens” and pre-designed defensive lines.

The next-stage questions will be more clinical, and stricter. If the Phase II trial begins, researchers will need to show that the immune response is not only a signal measurable in the laboratory, but also clarify dosage, durability, differences in response across different populations, and interactions with existing COVID-19 vaccines or post-infection immune backgrounds. For a product described as a universal coronavirus vaccine, passing early safety testing is only the entrance point. The real test is whether its broad-spectrum premise can hold up amid real-world viral diversity.